United States

Neurana Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek® National Conference

Lead Product(s): Tolperisone

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 02, 2020

Details:

The presentation will highlight results from a double-blind, randomized, placebo-controlled, multicenter phase 3 study evaluating Tolperisone 100 and 200 mg Three Times Daily (TID) for acute muscle spasm of the back.

ANTARES PHARMA INC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

First Commercial Product Using Antares Pharma’s Multi-Dose Pen Platform Launches in Europe

Lead Product(s): Teriparatide

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

Details:

Antares development partner Teva, launched Teriparatide Injection (“teriparatide”), the generic version of Eli Lilly’s brand product Forsteo® featuring the Antares multi-dose pen platform in Austria, Croatia, Hungary,

Pfenex

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Pfenex Announces Positive European CHMP Opinion for PF708

Lead Product(s): Teriparatide

Therapeutic Area: Musculoskeletal Product Name: Livogiva

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2020

Details:

Pfenex received a positive opinion for PF708 (branded in Europe as Livogiva™) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Amphastar Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial

Lead Product(s): Succinylcholine Chloride

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

Details:

The U.S. FDA has approved Abbreviated New Drug Application for Succinylcholine Chloride Injection USP, 200 mg/10 mL Multiple-Dose Vial. Amphastar’s drug product was determined by the FDA to be therapeutically equivalent to Succinylcholine Chloride Injection USP, 200 mg/10 mL.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Neurana Pharmaceuticals

Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek® National Conference

ANTARES PHARMA INC

First Commercial Product Using Antares Pharma’s Multi-Dose Pen Platform Launches in Europe

Pfenex

Pfenex Announces Positive European CHMP Opinion for PF708

Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial